View Single Post
Old 01-02-2014, 11:46 PM   #1
Senior Member
Join Date: Oct 2013
Posts: 425
Tivatinib (ARQ-197)

I dont know if this investigational drug has been mentioned before. It is an inhibitor of C-MET which is the Hepatocyte Growth Factor Tyrosine Kinase. Apparently C-Met is overactive in various cancers. Tivatinib has been tried in Non Small Cell Cancer of the lung and Hepatocellular Carcinoma with some positive results.

The usual dosage seems to be 360mg twice daily and the side effects are anemia, Neutropenia, Fatigue and appetite loss.

donocco is offline   Reply With Quote